Literature DB >> 9413055

The effect of radioimmunotherapy using murine monoclonal antibody KIS1 on esophageal squamous cell carcinoma-bearing nude mice.

T Fujii1, H Yamana, Y Toh, U Toh, H Fujita, K Shirouzu, M Morimatsu.   

Abstract

The monoclonal antibody (MoAb) KIS1 has been shown to react specifically with an antigen of human squamous cell carcinoma (SCC); however, a major problem in its clinical application is that the intact murine antibody induces a human anti-mouse antibody (HAMA). To overcome this problem, we produced the KIS1 F(ab')2 fragment, then radioiodinated the intact KIS1 antibody and its F(ab')2 fragment. Nude mice bearing human esophageal SCC implants were injected with 100 microCi of 131I-intact KIS1 or 131I-KIS1 F(ab')2, and images were obtained using a gamma camera. Radioimmunotherapy (RIT) was performed by injecting the tumor-bearing nude mice with 131I-intact KIS1 or 131I-KIS1 F(ab')2 at a dosage of 300 microCi, following which 7 or 3 days were required to produce high quality tumor images by scintigraphy. The tumor-bearing mice treated with 131I-KIS1 F(ab')2 showed significant tumor growth inhibition, about 5.4 times greater than that of the control group and 1.8 times greater than that of the 131I-intact KIS1 group 21 days after the injection. These results indicate that the KIS1 F(ab')2 fragment is superior to intact KIS1, and that it may be clinically useful for radioimmunodetection followed by tumor targeting therapy for patients with SCC of the esophagus.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9413055     DOI: 10.1007/bf02385783

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  26 in total

1.  Reduction by anti-antibody administration of the radiotoxicity associated with 131I-labeled antibody to carcinoembryonic antigen in cancer radioimmunotherapy.

Authors:  R D Blumenthal; R M Sharkey; D Snyder; D M Goldenberg
Journal:  J Natl Cancer Inst       Date:  1989-02-01       Impact factor: 13.506

2.  Radioimmunoscintigraphy of human pancreatic carcinoma xenografts in nude mice with 131I-labeled monoclonal antibody.

Authors:  T Tsuda; H Koshiba; T Usui; M Kubota; K Kikuchi; K Morita
Journal:  Ann Nucl Med       Date:  1990-07       Impact factor: 2.668

3.  Comparative biodistribution and radioimmunotherapy of monoclonal antibody RS7 and its F(ab')2 in nude mice bearing human tumor xenografts.

Authors:  R Stein; R Blumenthal; R M Sharkey; D M Goldenberg
Journal:  Cancer       Date:  1994-02-01       Impact factor: 6.860

4.  Enhancement of radioimmunotherapy by drugs modifying tumour blood flow in a colonic xenograft model.

Authors:  R B Pedley; R H Begent; J A Boden; G M Boxer; R Boden; P A Keep
Journal:  Int J Cancer       Date:  1994-06-15       Impact factor: 7.396

5.  Radiolocalization of xenografted human lung cancer with monoclonal antibody 8 in nude mice.

Authors:  K Endo; H Kamma; T Ogata
Journal:  Cancer Res       Date:  1987-10-15       Impact factor: 12.701

Review 6.  Monoclonal antibodies in cancer detection and therapy.

Authors:  D M Goldenberg
Journal:  Am J Med       Date:  1993-03       Impact factor: 4.965

7.  Comparative localization of murine monoclonal antibody Me1-14 F(ab')2 fragment and whole IgG2a in human glioma xenografts.

Authors:  E V Colapinto; P A Humphrey; M R Zalutsky; D R Groothuis; H S Friedman; N de Tribolet; S Carrel; D D Bigner
Journal:  Cancer Res       Date:  1988-10-15       Impact factor: 12.701

8.  Improved radioimaging and tumor localization with monoclonal F(ab')2.

Authors:  R L Wahl; C W Parker; G W Philpott
Journal:  J Nucl Med       Date:  1983-04       Impact factor: 10.057

9.  Effect of hyperthermia on tumor uptake of radiolabeled anti-neural cell adhesion molecule antibody in small-cell lung cancer xenografts.

Authors:  M N Hosono; M Hosono; K Endo; R Ueda; Y Onoyama
Journal:  J Nucl Med       Date:  1994-03       Impact factor: 10.057

10.  Comparative radioimmunotherapy using intact or F(ab')2 fragments of 131I anti-CEA antibody in a colonic xenograft model.

Authors:  R B Pedley; J A Boden; R Boden; R Dale; R H Begent
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.